Published in:
Open Access
01-12-2010 | Poster presentation
Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL
Authors:
JL Casado, P Domingo, R Rubio, A Antela, MA Lopez-Ruz, A Castro, J Portilla, E Ribera, D Podzamczer, JA Oteo, J Galindo, S Otero, F Lozano, V Estrada, J Moltó, S Moreno
Published in:
Journal of the International AIDS Society
|
Special Issue 4/2010
Login to get access
Excerpt
The administration of 200 mg of RTV to boost TPV plasma levels is associated with poor tolerance and toxicity. Some studies have shown that 100 mg of RTV could be enough to reach plasma levels of TPV that inhibit most HIV strains. This clinical trial was designed to show the efficacy and tolerability of switching to TPV 500/RTV 100 in patients with suppressed viremia receiving TPV 500/RTV 200. …